Cleveland Clinic CRISPR therapy halves bad cholesterol for a year
A Cleveland Clinic trial showed a single CRISPR dose reduced LDL cholesterol and triglycerides by half in patients with lipid disorders one year after treatment.
Study results after twelve months
Researchers followed fifteen participants to see if earlier benefits lasted. The highest dose lowered LDL levels by 52.5 percent and triglycerides by 47.8 percent at the one-year mark. These reductions remained present throughout the entire follow-up period.
Safety profile during trial
The team monitored patients for serious problems related to the gene-editing process. No severe adverse events connected to the therapy occurred during the year of observation. The study was published in the New England Journal of Medicine.
Presentation at European meeting
Medical professionals shared these findings at the 2026 European Society of Cardiology annual gathering. The data builds on initial reports from November 2025 regarding short-term effects. This trial represents a first-in-human Phase 1 clinical investigation.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.